AMRTx Pipeline

AMRTx’ Solutions

Novel Anti-infective Drugs Pipeline of Lead Compounds

AMRTx has filed two U.S. provisional patents - Serial No. 63/431, 601 and 63/431,604, with the complete freedom to operate.


  • Five small-molecule leads (ATX1-5) inhibit the activation of sortase A dimer and the subsequent bacterial invasion of mammalian cells - early stage treatment.
  • Protein (ATPC) and peptide (ATPN1) antagonize the bacterial invasion of mammalian cells by blocking the signals activating Sortase A enzyme - pre-early stage treatment.


  • Wave 2 Machine Vision accurately predicted the ATPC and ATPN1.
  • Wave 3 Generative AI designed optimized second generation ATX-B1 compound.

Let's build something great together.

Contact Us